Pain and cancer are closely linked. The cancer patient not only has to deal with the potentially painful direct assault by malignant cells and tissue but also has to suffer the robust treatments that often incur a significant physical and mental cost. The Association for Palliative Medicine (APM) and British Pain Society (BPS) Working Group for Pain in Cancer Patients have been convened to investigate, educate and inform about pain in cancer patients. This edition of the British Journal of Pain (BJP) is part of the work stream of this Group and aims to enlighten by updates from experts concerning key themes integral to pain in the cancer patient, from basic science to organisation of integrated service provision.
Research has previously attempted to identify mechanisms peculiar to cancer pain and that can therefore be targeted by novel, specific anti-cancer pain therapies. The relative limitation of available analgesic drugs for both cancer and non-cancer pain has restricted the exploitation of those differences, and the pharmaceutical tools have been similar for both patient groups. However, the growing body of work into models of cancer pain has put specific anti-cancer pain methodologies back on the agenda. Professor Dickenson's exploration into pathophysiological changes preludes the possibility of the development of future novel and specific targets for cancer pain.
Opioids remain the mainstay of pharmacological management of many acute and chronic pains, in cancer patients or in those with non-malignant aetiologies. Nevertheless, these agents are beset with the vagaries of side effects and major issues with long-term treatment. There is a clear tension between reducing barriers to achieve effective opioid-based analgesia and the apparently contrary position of avoidance of opioids because of short-and long-term toxicity and abuse potential. Thriving emergent technologies of genetics and pharmacogenomics are revealing the complicated intricacies of opioid function with the prospect individualised opioid management that could potentially minimise the harmful potential yet retaining analgesic efficiency of opioids. This diversity of the mechanisms of opioid action is explored in the treatise of splice variation of the mu-opioid receptor.
Pain in cancer patients is often mislabelled as 'cancer pain'. The increasing prevalence of pain in cancer survivors (whose number is forecast to double by 2030) is creating a growing body of patients with a symptom burden predominantly secondary to the treatment of cancer rather than the cancer per se. This survivorship population risks being left in a therapeutic desert unable to access services although their symptoms may be as challenging and debilitating as from the cancer they thought they had assuaged. These are patients who will become more prevalent in most pain practices. Education will be key to improving recognition, assessment and treatment of these survivors.
Earlier exposure (in the cancer journey) to services previously labelled 'Palliative care' has long been expounded and indeed improves many patient-centred quality outcomes. Nationally, there appears to be a movement to re-brand to the more accurately described 'symptom control' or 'supportive care team'. This semantic change potentially refutes the assumption that 'palliative care' involves only the final stages of life. These adjustments lend themselves to a more integrative multidisciplinary approach. Models and approaches to facilitate implementation of this earlier integrative practice are discussed and comprise a key activity stream of the APM/BPS Working Group. Guest Editorial
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